Literature DB >> 21123451

BCR/ABL stimulates WRN to promote survival and genomic instability.

Artur Slupianek1, Tomasz Poplawski, Stanislaw K Jozwiakowski, Kimberly Cramer, Dariusz Pytel, Ewelina Stoczynska, Michal O Nowicki, Janusz Blasiak, Tomasz Skorski.   

Abstract

BCR/ABL-transformed chronic myeloid leukemia (CML) cells accumulate numerous DNA double-strand breaks (DSB) induced by reactive oxygen species (ROS) and genotoxic agents. To repair these lesions BCR/ABL stimulate unfaithful DSB repair pathways, homologous recombination repair (HRR), nonhomologous end-joining (NHEJ), and single-strand annealing (SSA). Here, we show that BCR/ABL enhances the expression and increase nuclear localization of WRN (mutated in Werner syndrome), which is required for processing DSB ends during the repair. Other fusion tyrosine kinases (FTK), such as TEL/ABL, TEL/JAK2, TEL/PDGFβR, and NPM/ALK also elevate WRN. BCR/ABL induces WRN mRNA and protein expression in part by c-MYC-mediated activation of transcription and Bcl-xL-dependent inhibition of caspase-dependent cleavage, respectively. WRN is in complex with BCR/ABL resulting in WRN tyrosine phosphorylation and stimulation of its helicase and exonuclease activities. Activated WRN protects BCR/ABL-positive cells from the lethal effect of oxidative and genotoxic stresses, which causes DSBs. In addition, WRN promotes unfaithful recombination-dependent repair mechanisms HRR and SSA, and enhances the loss of DNA bases during NHEJ in leukemia cells. In summary, we postulate that BCR/ABL-mediated stimulation of WRN modulates the efficiency and fidelity of major DSB repair mechanisms to protect leukemia cells from apoptosis and to facilitate genomic instability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123451      PMCID: PMC3032814          DOI: 10.1158/0008-5472.CAN-10-1066

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  A functional interaction of Ku with Werner exonuclease facilitates digestion of damaged DNA.

Authors:  D K Orren; A Machwe; P Karmakar; J Piotrowski; M P Cooper; V A Bohr
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis.

Authors:  Malgorzata Nieborowska-Skorska; Grazyna Hoser; Plamen Kossev; Mariusz A Wasik; Tomasz Skorski
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins.

Authors:  Nicola Brady; Terry J Gaymes; Manyee Cheung; Ghulam J Mufti; Feyruz V Rassool
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

4.  Non-homologous end joining as an important mutagenic process in cell cycle-arrested cells.

Authors:  Erich Heidenreich; Rene Novotny; Bernd Kneidinger; Veronika Holzmann; Ulrike Wintersberger
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

5.  Chronic myelogenous leukemia molecular signature.

Authors:  Michal Oskar Nowicki; Peter Pawlowski; Thomas Fischer; Georg Hess; Tomasz Pawlowski; Tomasz Skorski
Journal:  Oncogene       Date:  2003-06-19       Impact factor: 9.867

6.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

Authors:  A Slupianek; C Schmutte; G Tombline; M Nieborowska-Skorska; G Hoser; M O Nowicki; A J Pierce; R Fishel; T Skorski
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

7.  Nuclear translocation of insulin receptor substrate-1 by the insulin receptor in mouse embryo fibroblasts.

Authors:  An Wu; Laura Sciacca; Renato Baserga
Journal:  J Cell Physiol       Date:  2003-06       Impact factor: 6.384

8.  Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer.

Authors:  Terry J Gaymes; Ghulam J Mufti; Feyruz V Rassool
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

9.  Werner syndrome protein limits MYC-induced cellular senescence.

Authors:  Carla Grandori; Kou-Juey Wu; Paula Fernandez; Celine Ngouenet; Jonathan Grim; Bruce E Clurman; Michael J Moser; Junko Oshima; David W Russell; Karen Swisshelm; Scott Frank; Bruno Amati; Riccardo Dalla-Favera; Raymond J Monnat
Journal:  Genes Dev       Date:  2003-07-01       Impact factor: 11.361

10.  WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair.

Authors:  Lishan Chen; Shurong Huang; Lin Lee; Albert Davalos; Robert H Schiestl; Judith Campisi; Junko Oshima
Journal:  Aging Cell       Date:  2003-08       Impact factor: 9.304

View more
  26 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 2.  The role of RecQ helicases in non-homologous end-joining.

Authors:  Guido Keijzers; Scott Maynard; Raghavendra A Shamanna; Lene Juel Rasmussen; Deborah L Croteau; Vilhelm A Bohr
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-07-22       Impact factor: 8.250

Review 3.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

4.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Authors:  Margaret Nieborowska-Skorska; Piotr K Kopinski; Regina Ray; Grazyna Hoser; Danielle Ngaba; Sylwia Flis; Kimberly Cramer; Mamatha M Reddy; Mateusz Koptyra; Tyrone Penserga; Eliza Glodkowska-Mrowka; Elisabeth Bolton; Tessa L Holyoake; Connie J Eaves; Sabine Cerny-Reiterer; Peter Valent; Andreas Hochhaus; Timothy P Hughes; Heiko van der Kuip; Martin Sattler; Wieslaw Wiktor-Jedrzejczak; Christine Richardson; Adrienne Dorrance; Tomasz Stoklosa; David A Williams; Tomasz Skorski
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

5.  Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.

Authors:  Anna Virgili; Mateusz Koptyra; Yashodhara Dasgupta; Eliza Glodkowska-Mrowka; Tomasz Stoklosa; Elisabeth P Nacheva; Tomasz Skorski
Journal:  Cancer Res       Date:  2011-06-21       Impact factor: 12.701

6.  Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.

Authors:  Warren Fiskus; Srdan Verstovsek; Taghi Manshouri; Rekha Rao; Ramesh Balusu; Sreedhar Venkannagari; Nalabothula Narasimha Rao; Kyungsoo Ha; Jacqueline E Smith; Stacey L Hembruff; Sunil Abhyankar; Joseph McGuirk; Kapil N Bhalla
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

7.  Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining.

Authors:  Sujata Chakraborty; Jeremy M Stark; Can-Lan Sun; Hardik Modi; WenYong Chen; Timothy R O'Connor; Stephen J Forman; Smita Bhatia; Ravi Bhatia
Journal:  Blood       Date:  2012-04-04       Impact factor: 22.113

8.  BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Authors:  A Slupianek; R Falinski; P Znojek; T Stoklosa; S Flis; V Doneddu; D Pytel; E Synowiec; J Blasiak; A Bellacosa; T Skorski
Journal:  Leukemia       Date:  2012-10-09       Impact factor: 11.528

9.  PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.

Authors:  Paulina Podszywalow-Bartnicka; Silvia Maifrede; Bac Viet Le; Margaret Nieborowska-Skorska; Katarzyna Piwocka; Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2018-06-22

10.  Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Authors:  Margaret Nieborowska-Skorska; Katherine Sullivan; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Grazyna Hoser; Silvia Maifrede; Esteban Martinez; Daniela Di Marcantonio; Elisabeth Bolton-Gillespie; Kimberly Cramer-Morales; Jaewong Lee; Min Li; Artur Slupianek; Daniel Gritsyuk; Sabine Cerny-Reiterer; Ilona Seferynska; Tomasz Stoklosa; Lars Bullinger; Huaqing Zhao; Vera Gorbunova; Katarzyna Piwocka; Peter Valent; Curt I Civin; Markus Muschen; John E Dick; Jean Cy Wang; Smita Bhatia; Ravi Bhatia; Kolja Eppert; Mark D Minden; Stephen M Sykes; Tomasz Skorski
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.